TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Denervation of the renAl sympathetIc nerveS in hearT Failure With nOrmal Lv Ejection Fraction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Individual is diagnosed with heart failure with a normal LV ejection fraction. The diagnosis of HFNEF requires the following conditions to be satisfied:~  * signs or symptoms of heart failure;~ * normal or mildly abnormal systolic LV function (LVEF ≥ 50%);~ * evidence of diastolic LV dysfunction.~* Individual should fulfill the diagnostic WHO criteria for hypertension: SBP \> 140 mmHg and/or DBP \> 90 mmHg, and is treated with at least 2 antihypertensive drugs. This treatment is expected to be maintained for at least 6 months. Using this regimen the blood pressure should be adequately controlled (\< 140/90mmHg by 24 hour ambulatory BP measurement).~* Individual is adhering to a stable drug regimen HFNEF, with no changes for a minimum of 2 weeks prior to enrollment, and which is expected to be maintained for at least 6 months.~* Individual is ≥ 18 years of age.~Exclusion Criteria:~* Known secondary cause of hypertension~* Anatomy not eligible for renal denervation~* Systolic heart failure (LVEF \< 50%)~* Individual has an estimated glomerular filtration rate (eGFR) of \< 30mL/min/1.73m2, using the MDRD calculation.~* Individual has any serious medical condition, which in the opinion of the investigator, may adversely affect the safety and/or effectiveness of the participant or the study (i.e., patients with clinically significant peripheral vascular disease, abdominal aortic aneurysm, bleeding disorders such as thrombocytopenia, haemophilia, significant anaemia, or arrhythmias such as atrial fibrillation).~* Individual is pregnant, nursing or planning to be pregnant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Renal denervation (Type: EXPERIMENTAL): Renal denervation
- control (Type: NO_INTERVENTION): No intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: CytID Analysis of Oral Lesions

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Receive care at the Avenue 360 Health and Wellness Clinic, a not for profit dental clinic in the Montrose area of Houston~* Present with a potentially malignant oral lesion (PMOL) for whom a biopsy is deemed necessary~Exclusion Criteria:~* Do not receive care at the Avenue 360 Health and Wellness Clinic, a not for profit dental clinic in the Montrose area of Houston~* Do not present with a potentially malignant oral lesion (PMOL) for whom a biopsy is deemed necessary

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Oral examination followed by biopsy, CytID, and hpvID (Type: None): Identification of oral lesions with oral examination with both incandescent light and fluorescent light (OralID), and subsequent testing of suspicious oral lesions with biopsy, CytID, and hpvID

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically confirmed primary cutaneous T-cell lymphoma (CTCL)~2. Age ≥ 18 years~3. Performance status WHO\<=2~4. Subject must have adequate bone marrow, renal and hepatic function~5. Topical and phototherapy treatment failure in the past~6. Signed informed consent~Exclusion Criteria:~1. Subject has received prior systemic methotrexate or interferon therapy~2. Unacceptable methotrexate or interferon treatment toxicity in the past~3. Inadequate bone marrow, renal or hepatic function as follows:~   * Bone Marrow: Absolute neutrophil count (ANC) \< 1,500/mm 3 (1.5 × 10 9 /L); Platelets \<100,000/mm 3 (100 × 10 9 /L); Hemoglobin \< 9.0 g/dL (1.4 mmol/L);~  * Renal function: Creatinine \>1.5 x Upper limit of normal (ULN)~  * Hepatic function: Aspartate and Alanine transaminase (AST and ALT) \>3× ULN; bilirubin \> 1.5 × ULN~  * Active hepatitis B or hepatitis C~4. anorexia~5. major depression with suicidal ideation or suicide attempt in the past~6. Symptomatic congestive heart failure~7. Epilepsia or other symptomatic central nervous system dysfunction~8. active skin infection not related to underlying CTCL, active Tuberculosis, HIV infection~9. Subject is pregnant or lactating~10. Psychiatric illness/social situation that would limit compliance with study requirements

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Methotrexate arm (Type: ACTIVE_COMPARATOR): Patients assigned to receive methotrexate
- Interferon Alfa-2b (Type: ACTIVE_COMPARATOR): Patients assigned to receive Interferon alfa 2b

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Palatability of a Nutritional Support Biscuit (Fitabisc)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients between the ages of 16 and 80 years inclusive.~* Patients who are having colorectal surgery.~* Patients who are able to give voluntary, written informed consent to participate in the study and from whom written consent has been obtained.~Exclusion Criteria:~* Those who cannot or do not provide informed consent~* Patients with a known or suspected allergy to any of the ingredients of Fitabisc e.g. gluten or dairy products~* Patients with one of the following co-morbidities:~  * Haemochromatosis~ * Thalassaemia~ * Kidney disease~ * Liver disease~ * Reye syndrome~* Patients who already take supplements of vitamin C, E, selenium or glutamine.~* Patients with type 1 diabetes, or type 2 diabetes that requires them to have insulin or a hypoglycaemic drug such as Metformin.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of a Home Delivered Meal Program on Obese Elderly African American Subjects With Type 2 Diabetes Mellitus (DM)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. African-American subjects~2. Males or females 65 - 85 years of age~3. Body mass index (BMI) equal to or greater than 30 kg/m2~4. Fasting blood glucose less than 300 mg/dL and HbA1c less than 9.0%~5. Ability to understand and be willing to adhere to the study protocol~6. A known history of type 2 diabetes mellitus greater than 3 months, receiving either diet alone or oral antidiabetic agents (sulfonylureas, metformin, thiazolidinediones).~Exclusion Criteria:~1. Subjects with a history of diabetic ketoacidosis and hyperosmolar hyperglycemic state.~2. Patients with clinically relevant hepatic disease or impaired renal function, as shown by a serum creatinine greater than 3.0 mg/dL.~3. Mental condition rendering the subject unable to understand the scope of the study.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): A total of 20 African-American patients with type 2 diabetes will be randomized to receive home-delivered meals for twelve consecutive months. In addition, the subjects received diabetes education at every visit (8 clinic visits and 8 phone calls)
- 2 (Type: EXPERIMENTAL): A total of 20 African-American patients with type 2 diabetes will be randomized to receive home-delivered meals for six consecutive months. In addition, the subjects received diabetes education for up to twelve months(8 clinic visits and 8 phone calls)
- 3 (Type: OTHER): 20 subjects received 12 months of diabetes education (8 clinic visits and 8 phone calls)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Smoking Cessation Intervention Within the Fracture Clinic

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~patients greater than 18 years patients sustained an injury resulting in a fracture date of recruitment is the initial clinic/consultation/post operative visit. clinic visit is within and including 14 days from initial date of injury or operation~Exclusion Criteria:~Patients presenting to the fracture clinic that:~* Do not meet inclusion criteria~* Are currently following cessation therapy~* Cannot understand or read English or French~* Have abused alcohol within the last six months~* Have abused illicit drugs within the last six months~* Are Pregnant or breast feeding~* Have sustained a pathologic fracture~Definitions~Fractures:~Following fractures are considered one fracture~* Single or combination of fractures involving hand including and distal to proximal row carpal bones~* Single or combination of fractures involving foot including and distal to the midfoot~* Fractures involving radius and ulna presenting at the same level (ie. Distal,diaphyseal, or proximal as per AO classification)~* Fractures involving tibia and fibula presenting at the same level (ie. Distal,diaphyseal, or proximal as per AO classification)~Polytrauma:~Defined as traumatic incident that has resulted in injury to more than just the MSK system at time of index injury~Spinal Trauma:~Defined as sustaining fracture, subluxation, dislocation, disc herniation or neurologic deficit attributed o spinal injury at time of index injury~Neurovascular Compromise:~Defined as complete loss of motor or cutaneous sensation loss at time of index injury~Illicit substance/drug abuse:~Defined as use of illicit substance or non prescribed narcotic within six months of injury~Alcohol Abuse:~Defined as use of alcohol and positive CAGE questionnaire screening~Pathologic/Insufficiency Fracture:~Fracture secondary to osteoporosis/osteopenia, malignant or non malignant lesion, bisphosphonate use

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Group A (Type: NO_INTERVENTION): Group A - smoking cessation with no assistance
- Group B (Type: PLACEBO_COMPARATOR): Group B - smoking cessation with the addition of a smoking cessation patch

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Serving Women Using Opioids During Pregnancy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Currently pregnant~* Taking opioids (prescription opioids, methadone, suboxone, heroin, kratom, etc.)~* Fluent in English~Exclusion Criteria:~* Past experiences with mindfulness-based stress reduction, mindfulness-based relapse prevention, mindfulness-based cognitive therapy~* Active suicidality~* Active psychosis

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Mindfulness (Type: EXPERIMENTAL): MORE is a manualized integrative treatment strategy that targets transdiagnostic mechanisms in stress-related conditions. MORE is made up of three primary components: mindfulness training, cognitive restructuring, and savoring. Mindfulness training aims to increase attentional control to reduce cognitive bias toward negative information. Cognitive reappraisal promotes restructuring of maladaptive cognitions, which would otherwise intensify negative emotion and addictive behavior. Finally, MORE promotes savoring - mindful attention to and appreciation of pleasant events in life as a means of increasing positive emotion regulation.
- Supportive Psychotherapy (Type: ACTIVE_COMPARATOR): Supportive psychotherapy is a form of non-directive talk therapy, which follows a Rogerian person-centered approach. The therapist's primary objectives during a session will be (1) to communicate unconditional positive regard for the participant, (2) to communicate engagement and empathic understanding, and (3) to mirror a participant's affect.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Determine the Immunogenicity and Oral Tolerance to Keyhole Limpet Hemocyanin (KLH)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy~* Ability to give informed consent and comply with study procedures.~* Participant able/willing to hold off receiving prophylactic immunizations (like influenza or pneumococcal vaccines) during the study period.~Exclusion Criteria:~* Use of corticosteroids within 2 weeks prior to screening visit.~* First degree relative (parent, sibling or child) with history of autoimmune disease.~* Presence of chronic medical illness including but not limited to chronic kidney-, liver-, cardio-vascular diseases, immunodeficiencies, anemia, B12 deficiency, malignancies, or chronic active infections.~* History of acute gastrointestinal illness within 2 weeks prior to oral KLH administration.~* For women of child bearing age, participant unwilling to defer pregnancy, has a positive urine pregnancy test or is currently pregnant or lactating.~* Use of an investigational drug within 3 months of the screening visit.~* History of acute febrile illness within 1 week of screening visit.~* History of allergy to shellfish, previous exposure to KLH/product containing KLH or known-sensitivity to KLH / components of KLH preparation.~* Participants receiving any immunizations within 1 month prior to screening visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Immucothel alone (Part A) (Type: EXPERIMENTAL): 100 µg Immucothel subcutaneously (SQ) on Day 0 and Day 9.
- Immucothel+Montanide (Part A) (Type: EXPERIMENTAL): If an immune response was not observed in at least nine out of the first 10 participants after receiving Immucothel alone, 10 additional healthy subjects would be recruited and immunized with Immucothel (SQ) plus Montanide (SQ) on Day 0 and Day 9.
- Immucothel alone or Immucothel+Montanide (Part B) (Type: EXPERIMENTAL): Dependent on the results for Part A.~Briefly: Ten new, healthy participants were to be fed 50 mg of native keyhole limpet hemocyanin (KLH), a protein extracted from a mollusk (a sea animal), on Days 0 through 4 and Days 10 through 14, for a total dose of 500 mg. The participants were then immunized using the strategy that produced an immune response in at least nine out of 10 participants in Part A (Immucothel alone or Immucothel plus Montanide) on Days 26 and 35.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Bupropion for Depression in ESRD Patients on Hemodialysis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age 30-70 yrs;~* have patent and non-infected arteriovenous fistula or graft;~* are receiving maintenance HD 3 times per week lasting for 3-4 hours;~* serum albumin of ≥ 3.2 g/dl, serum phosphate of \<6.5 mg/dl, and serum hemoglobin of ≥9 mg/dl in consecutive two blood tests as per the National Kidney Foundation Disease Outcomes Quality Initiative (NKF KDOQI) guidelines \[subjects failing screening due to blood test will be allowed to be re-screened in 30 days\];~* receiving stable or maintenance dose of iron or erythropoietin-stimulating agents, statins, angiotension receptor blockers and/or angiotension converting enzyme inhibitors, phosphate binders, vitamin D receptor analogs as these agents may influence cytokines proposed in the study;~* meet the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) criteria for MDD;~* have a Ham-D score \> 17~Exclusion Criteria:~* meet DSM-IV criteria for Bipolar Disorder or other psychotic disorder in the month prior to screening;~* are taking antidepressants, anti-anxiety medications, or hypnotics (including Zyban for smoking cessation);~* having failed to respond to or tolerate bupropion or fluoxetine in the past~* allergic to fluoxetine or bupropion~* known history of HIV/AIDS; No testing will be conducted for screening purposes~* known history of alcohol or drug abuse or dependence within the month prior to screening based on clinical records;~* history of myocardial infarction or heart failure within one month of screening or a history of seizures or stroke at any point;~* history of chronic liver disease and diagnosis of hepatic encephalopathy based on clinical records;~* currently diagnosed with cancer or receiving any cancer treatment;~* history of any infection within the last 2 weeks ;~* currently taking any antibiotics, anti-inflammatory, and immune-modulator agents;~* recorded noncompliance with dialysis schedules; and~* currently participating in clinical or behavioral intervention studies.~* recorded noncompliance with dialysis schedules; and~* currently participating in clinical or behavioral intervention studies

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Fluoxetine (Type: ACTIVE_COMPARATOR): Fluoxetine up to 20 mg orally daily for 12 weeks. Flexible dosing between a minimum of 10 mg daily and 20 mg daily as tolerated.
- Bupropion (Type: EXPERIMENTAL): Bupropion sustained release (SR) 150 mg orally twice per week

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Group Treatment for Adolescents With Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* English speaking~* male or female, ages 14 to 19, all races and ethnicities~* Current depression as assessed by an ALIFE - PSR score equal to or greater than 4~* Has a treating psychiatrist at Sunnybrook Health Sciences Centre~Exclusion Criteria:~* Current manic episode~* current psychosis

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: 19 Years
- Healthy Volunteers: f

Study Arms:
- Dialectical Behavior Therapy Skills Group (Type: EXPERIMENTAL): Twelve week skills based group therapy include four modules: mindfulness, emotion regulation, distress tolerance, and walking the middle path
- Psychoeducation group treatment (Type: EXPERIMENTAL): The comparison group used in the present study is based on a publicly available treatment manual from the Services for Teens At Risk (STAR) Center at the University of Pittsburgh

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Concurrent Training in Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male sex~* White British/European~* Aged between 40 and 65 years at the time of screening~* Have a body mass index (BMI; body weight/height in m2) between 27 and 40 kg/m2~* Sedentary/untrained for at least 1 year (based on physical activity self-reports of fewer than two sessions of structured exercise per week last \<30 min)~* T2DM (American Diabetes Association 2014) for more than 1 year~* Central obesity (defined as waist circumference ≥94 cm for males)~Exclusion Criteria:~* Currently involved in research or have recently (\<6 months) been involved in any research prior to recruitment~* Any condition limiting or contraindicating physical activity; including diabetic peripheral neuropathy, and coronary or peripheral artery disease~* Previous myocardial infarction, previous or current angina, shortness of breath, or other symptoms suggestive of heart failure~* Insulin medication~* HbA1c more than 75 mmol/mol (9%)~* Uncontrollable hypertension: systolic blood pressure ≥160 mmHg and diastolic blood pressure ≥100 mmHg~* Not weight stable for the last three months~* Smokers (within the last 12 months)~* Anticoagulant medication, such as warfarin or newer anticoagulant drugs. If participants are on aspirin medication, this would need to be stopped for 3 days prior to and during the day of any biopsy visit unless contraindicated (in which case participants would be excluded).

- Gender: MALE
- Minimum Age: 40 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- RE training only (Type: OTHER): RE only - Progressive resistance exercise training only (leg extension, leg step up, chest press and pull down).
- Concurrent RE + HIIT (Type: EXPERIMENTAL): RE + HIIT - Progressive resistance exercise training (leg extension, leg step up, chest press and pull down) followed by HIIT (10 x 1 min at 90% heart rate maximum).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues